Welcome to our dedicated page for HEARTCORE ENTERPRISES SEC filings (Ticker: HTCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HeartCore Enterprises, Inc. (Nasdaq: HTCR) SEC filings page provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on HeartCore’s enterprise software operations, Go IPOSM consulting services, capital structure, and significant corporate events.
Investors can review current reports on Form 8-K that describe material events such as the authorization of a one-time payment to stockholders, notices from Nasdaq regarding listing standards, and the sale of the company’s Japanese software subsidiary. Certain 8-K filings also discuss strategic decisions to focus on the Go IPOSM consulting business and to evaluate alternatives for divesting interests in other software-related entities.
HeartCore’s registration statements, including amendments on Form S-1, outline its business overview, risk factors, and financing arrangements. These filings describe the company’s customer experience management platform, digital transformation division, and IPO consulting activities, as well as equity purchase agreements and preferred stock issuances. They also explain how HeartCore may issue shares over time to institutional investors under specified agreements.
Periodic reports such as Forms 10-Q and 10-K (when available in the filing list) provide financial statements, segment information, and management’s discussion of results across software and consulting lines. These documents include details on revenues, gross profit, operating expenses, and non-GAAP measures like adjusted EBITDA, together with explanations of how those measures are calculated.
This page also helps track Nasdaq compliance disclosures related to minimum stockholders’ equity and minimum bid price requirements, as reported through Form 8-K. Users interested in governance matters can consult filings that summarize annual meeting results, including director elections and auditor ratification.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of equity financing agreements, asset sales, or changes in business focus. Real-time updates from EDGAR, combined with structured access to Forms 10-K, 10-Q, 8-K, S-1, and related exhibits, make this page a central resource for analyzing HTCR’s regulatory history and ongoing disclosure obligations.
HeartCore Enterprises (HTCR) reported it received an additional 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement under Rule 5550(a)(2). The new deadline is May 1, 2026. If the closing bid price is at least $1.00 for a minimum of 10 consecutive business days during this period, the matter will be closed.
If compliance is not demonstrated, Nasdaq may initiate delisting, which the company could appeal to a Hearings Panel. HeartCore is evaluating potential actions, including a reverse stock split, but has made no decisions.
HeartCore Enterprises (HTCR) amended its 8-K to clarify stockholders’ equity following a completed divestiture. The company sold all equity interests of its Japan subsidiary, HeartCore Inc., to Smith Japan Holdings KK for ¥1,800,418,650, equivalent to approximately $12 million based on a ¥152.82/USD $1 rate, and the sale closed on October 31, 2025.
The purchase price includes staged components: a Closing Payment net of estimated debt; a ¥126,133,200 holdback payable on the later of 180 days after closing or the final net tangible assets determination; a ¥273,866,800 long-term holdback tied to multi-year licensing agreements; and ¥387,078,650 deferred consideration (including ¥322,700,000 principal at 6.65% per annum) due on October 31, 2028. A debt true-up may adjust proceeds based on final debt. Both parties agreed to transition services for six months.
Strategic shift: the company plans to concentrate on its Go IPO consulting business and is assessing alternatives to divest its 51% interest in Sigmaways, Inc. It states stockholders’ equity is in excess of $5,000,000 as of November 4, 2025.
HeartCore Enterprises (HTCR) sold its Japan software subsidiary, HeartCore Japan, to Smith Japan Holdings KK for ¥1,800,418,650 (approximately $12 million), subject to adjustment. The deal closed on October 31, 2025. Payment terms include a Closing Payment of ¥1,013,340,000 less estimated debt, a ¥126,133,200 holdback released after six months or upon final NTA determination, a ¥273,866,800 long‑term holdback tied to multi‑year licensing agreements, and ¥387,078,650 in deferred consideration (¥322,700,000 principal at 6.65% per annum) due October 31, 2028. A debt true‑up may be owed depending on final debt.
The parties agreed to mutual transition services for six months post‑close (accounting/reporting by HeartCore; HR by Purchaser). HeartCore stated it will concentrate on its Go IPO consulting business and is assessing strategic alternatives to divest its 51% interest in Sigmaways, Inc.
HeartCore Enterprises (HTCR) announced a one-time cash distribution of $0.13 per share to common stockholders. The company clarified that a prior press release mistakenly described the payment as a dividend; for U.S. federal tax purposes, it will be treated as a distribution.
Key dates: the record date is November 10, 2025, and the payment date is expected to be November 17, 2025. This update does not change the amount, only the classification and related tax treatment language communicated to investors.
HeartCore Enterprises (HTCR) declared a one-time dividend of $0.13 per share on its common stock. Stockholders of record as of November 10, 2025 will receive the dividend, which is expected to be paid on November 17, 2025. The company also furnished a related press release.
HeartCore Enterprises, Inc. reported the results of its 2025 virtual annual meeting of stockholders held on September 26, 2025. Stockholders elected five directors — Sumitaka Yamamoto, Ferdinand Groenewald, Kimio Hosaka, Yoonji Lee, and Koji Sato — each to serve a one-year term until the next annual meeting and until their successors are elected and qualified. Each nominee received approximately 15.7 million votes in favor, with minimal abstentions and broker non-votes reported.
Stockholders also ratified the appointment of MaloneBailey, LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, with 17,471,545 votes for, 55,422 against, and 877 abstentions. These results confirm continuity in both board leadership and the company’s external auditor.
HeartCore Enterprises amended its S-1 to disclose an Equity Purchase Agreement with Crom Structured Opportunities Fund I, LP that gives the company the right to direct the accredited selling stockholder to sell up to $25,000,000 of newly issued common stock during a Commitment Period running from June 30, 2025 to June 30, 2027 (subject to termination conditions). The filing shows 23,310,770 shares outstanding as of August 28, 2025 and models issuance of 20,833,333 shares under the agreement (at an assumed $1.20/share) plus conversion of Series A preferred into 1,955,555 common shares (assumed $1.125/share), illustrating material potential dilution. The document also lists transaction fees and references incorporated financial statements and exhibits.
HeartCore Enterprises amended its S-1 to disclose an Equity Purchase Agreement with Crom Structured Opportunities Fund I, LP that gives the company the right to direct the accredited selling stockholder to sell up to $25,000,000 of newly issued common stock during a Commitment Period running from June 30, 2025 to June 30, 2027 (subject to termination conditions). The filing shows 23,310,770 shares outstanding as of August 28, 2025 and models issuance of 20,833,333 shares under the agreement (at an assumed $1.20/share) plus conversion of Series A preferred into 1,955,555 common shares (assumed $1.125/share), illustrating material potential dilution. The document also lists transaction fees and references incorporated financial statements and exhibits.
HeartCore Enterprises, Inc. reports that Nasdaq has confirmed the company is back in compliance with the exchange’s minimum stockholders’ equity requirement. The company previously received a notice on May 24, 2025 stating it did not meet the $2,500,000 stockholders’ equity threshold and did not qualify under alternative market value or net income standards, although trading of its common stock on the Nasdaq Capital Market under the symbol HTCR was not immediately affected.
On August 19, 2025, Nasdaq reviewed HeartCore’s Form 10-Q for the period ended June 30, 2025, which showed stockholders’ equity of $3,559,017, and determined that the company now satisfies the equity listing rule and that the matter is closed. HeartCore also furnished a press release as an exhibit, providing additional communication about these developments.
HeartCore Enterprises, Inc. reported that its Go IPO client, rYojbaba Co., Ltd., has begun trading on The Nasdaq Capital Market under the symbol “RYOJ.” This highlights activity in HeartCore’s Go IPO advisory and support business.
HeartCore received an aggregate of $500,000 in initial fees and warrants to acquire 3% of rYojbaba’s common stock on a fully diluted basis, valued at approximately $1.35 million as of August 14, 2025. The company furnished, but did not file, a press release describing these developments as an exhibit.
HeartCore Enterprises, Inc. disclosed that director Heather Neville will resign from the Board effective September 1, 2025, and that Prakash Sadasivam will resign as Chief Strategy Officer and as a director effective August 31, 2025. The filing explicitly states both resignations were not the result of any disagreement with the company on its operations, policies or practices.
These departures remove a sitting director and the company’s Chief Strategy Officer within days of each other. The filing does not identify successors, transitional arrangements, or additional context; HeartCore’s common stock trades on the Nasdaq Capital Market under the ticker HTCR.